Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Francesca Bruce
To get their gene or cell therapies through health technology appraisals, companies need to agree to gather longer-term evidence, be upfront about what treatments can really deliver and remember to ask for patient input.
Novartis and German insurers have agreed a payment by outcomes deal for its CAR-T therapy Kymriah.
Vertex CEO Jeff Leiden has defended his company’s approach to pricing, as well as his $17m salary, at a heated UK public hearing on access to cystic fibrosis drug Orkambi.
Vertex, NHS (National Health Service) England, and the health technology appraisal body NICE have forgotten about patients in the impasse over access to cystic fibrosis drug Orkambi, says a patient representative who attended the recent hearing on the price of the drug.
Vertex has come under fire for its alleged extreme rigidity on pricing for its cystic fibrosis drug in England.
Medicines prepared in pharmacies are now exempt from patent law in the Netherlands, giving pharmacists greater scope to prepare their own versions of patented medicines.